<?xml version="1.0" encoding="UTF-8"?>
<p id="Par101">Clover Biopharmaceuticals has a subunit vaccine under development. It is a highly purified recombinant SARS-CoV-2 S protein subunit-trimer vaccine (S-Trimer) and they produced it by using their Trimer-Tag© technology. They have announced that it is now at the preclinical phase, but it is not clear when it will enter the market [
 <xref ref-type="bibr" rid="CR115">115</xref>].
</p>
